Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

Manufacturing Inspection Delays Could Impact Decision Due 27 March

In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.

business financial ideas concept with coins stack and alarmclock isolate background with free copyspace for your creativity ideas text
Celgene shareholders get a payout from BMS if ide-cel and two other drugs are approved by specific deadlines • Source: Shutterstock

Bristol-Myers Squibb Company and bluebird bio have managed to get their B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy idecabtagene vicleucel in to the US Food and Drug Administration with a fighting chance at making the deadline for a contingent value right (CVR) payout that Bristol owes Celgene Corporation shareholders under the companies’ 2019 merger agreement.

More from New Products

Pipeline Watch: Seventeen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By 

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

Unicycive Approaches Its First Approval, But In A Competitive Space

 

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

More from Scrip

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 

Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.